LOW FLAT RATE AUST-WIDE $9.90 DELIVERY INFO

Close Notification

Your cart does not contain any items

$340.95

Paperback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
03 May 2023
Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use.

Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.
Edited by:  
Imprint:   Academic Press Inc
Country of Publication:   United Kingdom
Edition:   2nd edition
Dimensions:   Height: 235mm,  Width: 191mm, 
Weight:   1.610kg
ISBN:   9780323913676
ISBN 10:   0323913679
Series:   Translational Epigenetics
Pages:   772
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active

Steven Gray is a Senior Clinical Scientist and Adjunct Assistant Professor in the Thoracic Oncology Research Group, Trinity Centre for Health Sciences at St. James's Hospital, Dublin, Ireland.

See Also